Hypothesis

Chronic mTORC1 activation in enterochromaffin (EC) cells suppresses tryptophan hydroxylase 1 (TPH1) activity, reducing serotonergic output and contributing to age‑associated intestinal motility decline. This repression occurs independently of mTORC1’s effects on intestinal stem cells or villus architecture, positioning EC‑cell serotonin as a proximate read‑out of the civilization‑versus‑survival dial.

Mechanistic Rationale

1. mTORC1‑S6K1 phosphorylates TPH1 – Emerging data show that S6K1 can phosphorylate serine residues on aromatic amino acid hydroxylases, decreasing their catalytic efficiency (4). In EC cells, sustained mTORC1‑S6K1 signaling would thus directly lower TPH1 turnover rates despite unchanged transcription.
2. TFEB sequestration limits tryptophan availability – mTORC1 phosphorylates and retains TFEB in the cytosol, inhibiting lysosomal biogenesis and autophagy‑mediated recycling of tryptophan pools (2). Reduced intracellular tryptophan limits substrate for TPH1, compounding the enzymatic inhibition.
3. Feedback from serotonin – Serotonin activates 5‑HT4 receptors on EC cells, stimulating cAMP‑PKA pathways that antagonize mTORC1 (5). Age‑related serotonin loss therefore removes a brake on mTORC1, creating a vicious cycle of further TPH1 suppression.

These mechanisms extend the "civilization‑versus‑survival" concept: when mTORC1 drives anabolic programs in EC cells, the cells prioritize growth‑related signaling over their neuroendocrine role, effectively abandoning the collective function of gut serotonin signaling.

Testable Predictions

• Prediction 1: EC‑cell‑specific Raptor knockout (eliminating mTORC1) in aged mice will increase TPH1 protein activity (measured by phospho‑TPH1 serine residues) and luminal serotonin levels without altering villus height.
• Prediction 2: Acute rapamycin treatment will raise EC‑cell serotonin only in mice with intact mTORC1; Raptor‑deficient EC cells will show no additional increase, indicating that rapamycin’s effect is mediated through mTORC1 inhibition.
• Prediction 3: Pharmacological activation of S6K1 (e.g., via MHY1485) in young EC‑cell cultures will decrease TPH1 enzymatic velocity and serotonin release, an effect rescued by the S6K1 inhibitor PF‑4708671.
• Prediction 4: Supplementing aged mice with tryptophan will partially restore serotonin levels only when mTORC1 activity is concurrently lowered, supporting the dual‑hit model of substrate limitation and enzyme inhibition.

Experimental Approach

• Generate Villin‑CreERT2;Raptor^fl/fl mice and induce recombination at 18 months of age. Measure TPH1 phosphorylation, serotonin content in colonic lavage, and colonic transit time via carmine red assay.
• Treat parallel cohorts with rapamycin (8 mg/kg diet) for 4 weeks and compare outcomes to Raptor‑deficient animals.
• Use primary EC‑cell isolations to assess tryptophan uptake (radiolabeled ^3H‑tryptophan) and lysosomal mass (LAMP1 staining) under mTORC1 modulation.
• Apply pharmacological S6K1 activators/inhibitors in cultured EC‑cell lines (e.g., BON cells) and quantify TPH1 activity via ^14C‑tryptophan conversion to ^14C‑5‑hydroxytryptophan.

Falsifiability

If EC‑cell‑specific mTORC1 loss fails to elevate TPH1 activity or serotonin, or if rapamycin increases serotonin equally in Raptor‑deficient and control animals, the hypothesis that mTORC1 directly represses TPH1 in EC cells would be refuted. Likewise, absence of S6K1‑mediated TPH1 phosphorylation in vitro would undermine the proposed enzymatic inhibition mechanism.

Implication: Validating this link would reveal a cell‑autonomous mechanism by which longevity‑promoting mTOR inhibition restores not only tissue structure but also the serotonergic "language" that coordinates gut motility, reframing geroprotective strategies as reinstatement of cellular civil cooperation rather than mere survival mode.